TY - JOUR
T1 - Budget impact of endovascular treatment for acute ischaemic stroke patients in the Netherlands for 2015-2021
AU - van den Berg, Lucie A.
AU - Berkhemer, Olvert
AU - Fransen, Puck S. S.
AU - Beumer, Debbie
AU - Majoie, Charles B. L.
AU - Dippel, Diederik W. J.
AU - van der Lugt, Aad J.
AU - van Oostenbrugge, Robert H.
AU - van Zwam, Wim B.
AU - Roos, Yvo
AU - Dijkgraaf, Marcel G. W.
AU - MR CLEAN Investigators
PY - 2023/6
Y1 - 2023/6
N2 - Introduction: Endovascular treatment (EVT) has been proven to be both effective and cost-effective for patients with acute ischaemic stroke. We investigated the budget impact of large-scale implementation of EVT for acute ischaemic stroke patients in the Netherlands for 2015–2021. Methods: An analysis was performed from a healthcare perspective as a preplanned substudy of the Multicenter Randomized Clinical trial of Endovascular Treatment for Acute Ischemic Stroke in the Netherlands (MR CLEAN). Estimated yearly costs during follow-up after stroke for patients who had or had not been treated with EVT as add-on to usual care were linked to numbers of new patients retrieved from 2 Dutch registries of EVT that started after the last inclusion in MR CLEAN (2014). Aggregated costs and costs per care sector were calculated based on prevalence using a population dynamic tool. Results: From 2015, the yearly number of new acute ischaemic stroke patients receiving EVT increased almost threefold, from 812 in 2015 to 2,370 in 2021. The introduction of EVT plus usual care resulted in estimated net annual savings that increased from € 2.9 million in 2015 to € 58 million in 2021. Conclusion: Offering EVT as add-on to usual care for acute ischaemic stroke patients was increasingly cost saving from a national healthcare perspective but affected distinct healthcare sectors differently.
AB - Introduction: Endovascular treatment (EVT) has been proven to be both effective and cost-effective for patients with acute ischaemic stroke. We investigated the budget impact of large-scale implementation of EVT for acute ischaemic stroke patients in the Netherlands for 2015–2021. Methods: An analysis was performed from a healthcare perspective as a preplanned substudy of the Multicenter Randomized Clinical trial of Endovascular Treatment for Acute Ischemic Stroke in the Netherlands (MR CLEAN). Estimated yearly costs during follow-up after stroke for patients who had or had not been treated with EVT as add-on to usual care were linked to numbers of new patients retrieved from 2 Dutch registries of EVT that started after the last inclusion in MR CLEAN (2014). Aggregated costs and costs per care sector were calculated based on prevalence using a population dynamic tool. Results: From 2015, the yearly number of new acute ischaemic stroke patients receiving EVT increased almost threefold, from 812 in 2015 to 2,370 in 2021. The introduction of EVT plus usual care resulted in estimated net annual savings that increased from € 2.9 million in 2015 to € 58 million in 2021. Conclusion: Offering EVT as add-on to usual care for acute ischaemic stroke patients was increasingly cost saving from a national healthcare perspective but affected distinct healthcare sectors differently.
KW - Ischaemic Stroke
KW - Endovascular Procedures
KW - Thrombectomy
KW - Economic Evaluation
KW - CARE
U2 - 10.1007/s12471-023-01788-x
DO - 10.1007/s12471-023-01788-x
M3 - Article
C2 - 37171711
SN - 1568-5888
VL - 31
SP - 254
EP - 259
JO - Netherlands Heart Journal
JF - Netherlands Heart Journal
IS - 6
ER -